The amount of the deal was not disclosed.
The company will use the capital to further develop its ChordArt™ technologies. A first in human clinical use will be advanced for 2018 as
well as the initiation of a clinical trial that will support the European approval (CE) of the product.
Founded in 2012 in Bern, Switzerland and led by Thomas Bauer, CEO, CoreMedic is developing ChordArt™, a novel heart valve repair system that will allow the treatment of patients suffering from mitral heart valve regurgitation.
The company, which has locations in Biel, Switzerland and Tuebingen, Germany, consists of a team of skilled and dedicated professionals with a diverse
background in medical application (surgeons and cardiologists), management, research and development, regulatory and quality assurance.